Viz.ai, a leader in AI-driven disease detection and care coordination, has partnered with Avicenna.AI, a prominent provider of AI-powered medical imaging solutions, to integrate Avicenna.AI’s CINA-iPE and CINA-ASPECTS tools into the Viz.ai One™ platform. This integration combines Avicenna.AI’s advanced AI algorithms with Viz.ai’s care coordination capabilities, offering radiologists and specialists enhanced insights from computed tomography (CT) scans. The goal is to improve decision-making speed and accuracy, ultimately driving better patient care.
Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has expanded its partnership with Avicenna.AI to integrate Avicenna.AI’s CINA-iPE and CINA-ASPECTS tools into the Viz.ai One™ platform. This integration strengthens Viz.ai’s mission to enhance patient care by providing clinicians with advanced, AI-driven insights that can accelerate decision-making and treatment for patients with neurovascular conditions and pulmonary embolism (PE).
The CINA-ASPECTS tool offers an automated assessment of the Alberta Stroke Program Early CT Score (ASPECTS) from CT brain images, providing clinicians with an objective and reliable measure of stroke severity. This technology allows healthcare professionals to quickly evaluate the extent of brain damage caused by a stroke, improving the speed and accuracy of stroke care. The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Avicenna.AI’s CINA-iPE and CINA-ASPECTS tools in March 2024, marking a significant milestone in AI technology for medical imaging.
The CINA-iPE tool, which detects incidental pulmonary embolism (PE) during routine CT scans, is designed to help address the challenge of delayed or missed diagnoses of PE—a potentially life-threatening blockage in a lung artery. Routine CT scans of the chest often reveal unsuspected cases of PE, yet studies show that as few as 25% of emboli are identified during initial interpretations. By combining Avicenna.AI’s CINA tools with Viz.ai One, healthcare teams can now receive more comprehensive, real-time insights, enabling faster, more informed decisions that can improve patient outcomes.
Justin Ryea, director of product at Viz.ai, emphasized the importance of this integration: “This expanded partnership with Avicenna.AI represents an important step forward in our mission to improve patient care through AI-powered clinical workflows. By integrating CINA-iPE and CINA-ASPECTS into Viz.ai One, we are providing clinicians with a more robust, all-in-one neurovascular solution that can help speed up the decision-making process and ensure patients receive the right treatment as quickly as possible.”
The integration with Viz.ai One further enhances real-time communication and coordination among care teams. By delivering critical insights directly to the clinicians, the combined platform helps optimize care pathways, ensuring patients receive the appropriate interventions at the right time.
Cyril Di Grandi, CEO of Avicenna.AI, expressed excitement about the collaboration: “Incorporating CINA-iPE and CINA-ASPECTS into Viz.ai’s platform will elevate the quality and efficiency of patient care. By empowering healthcare professionals with innovative tools, we can help diagnose life-threatening conditions faster and ensure timely follow-up care.”
Viz.ai continues to lead the way in AI-powered care coordination, used in over 1,700 hospitals and health systems across the U.S. and Europe. Its Viz.ai One platform helps clinicians quickly identify patients with suspected diseases, enabling rapid diagnosis and improving patient outcomes. With this expanded partnership, both Viz.ai and Avicenna.AI aim to transform the speed and accuracy of clinical decision-making, helping healthcare providers deliver the best possible care to their patients.
